← Leaderboards
Cornelia L Dekker
Stanford University
$13,121,812
Attributed
$13,338,021
Total exposure
33
Grants
26
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2005–18$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
Funding mix
By agency
NIH$13,338,021 · 33
By mechanism
U19$7,994,024 · 3
R01$3,179,275 · 1
M01$1,732,303 · 28
R21$432,419 · 1
Top collaborators
- Gregory M Enns2 shared
Most similar at Stanford University
Same institution · by research overlap
- David Bram Lewis$8,260,755
- Ann M Arvin$18,980,456
- Graham N George$1,918,094
- David K Hong$652,995
Others in their field
Top investigators on “Resources”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$688,986,350
- Bambra Strokes · Ppd Development Lp$526,656,217
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Eric S Lander · Whitehead Institute For Biomedical Res$341,717,134
- Eric Jeffrey Topol · Cleveland Clinic Lerner Col/Med-Cwru$311,514,701
Research focus
ResourcesVaccinesInfluenzaVaccinationEnrollmentAdultInfluenza Virus VaccineEvaluationClinical ResearchResearch PersonnelChildBloodImmune ResponseUnited States National Institutes Of HealthInstitutionComputer Retrieval Of Information On Scientific Projects DatabaseFundingSourceGrantBlood SpecimenLaboratoriesHuman SubjectDesignRandomized
Grant awards (47)
Clinical Core$604,143
U19 · FY2018 · AI · contact PI
Clinical Core$701,446
U19 · FY2017 · AI · contact PI
Clinical Core$1,102,031
U19 · FY2016 · AI · contact PI
Clinical Core$493,075
U19 · FY2015 · AI · contact PI
Clinical Core$711,321
U19 · FY2014 · AI · contact PI
Clinical Core$816,428
U19 · FY2013 · AI · contact PI
Clinical Core$1,001,600
U19 · FY2012 · AI · contact PI
Clinical Core$773,468
U19 · FY2011 · AI · contact PI
Metabolic and Immune Responses to Flu Vaccine in Mitochondrial Disease Patients$153,600
R21 · FY2011 · HD · contact PI
Clinical Core$771,188
U19 · FY2010 · AI · contact PI
Metabolic and Immune Responses to Flu Vaccine in Mitochondrial Disease Patients$278,819
R21 · FY2010 · HD · contact PI
Clinical Core$767,055
U19 · FY2009 · AI · contact PI
Clinical Research Core$252,269
U19 · FY2008 · AI · contact PI
CLINICAL TRIAL: INFLUENZA VACCINE ALONE OR WITH ALUMINUM HYDROXIDE TO HEALTHY YO$43,119
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: CIRCUMSPOROZOITE MALARIA VACCINE IN HEALTHY ADULTS 18 TO 45 YEAR$25,257
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: CD4 T-CELL IMMUNE RESPONSE TO INACTIVATED INFLUENZA VACCINE IN C$7,964
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: IMMUNE SENESCENCE IN THE ELDERLY: INFLUENZA VACCINE IN ADULTS OF$7,622
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: CLONAL B-CELL RESPONSES TO TRIVALENT CLONAL B-CELL RESPONSES TO$3,527
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: HEALTH IMPACT OF CONGENITAL CYTOMEGALOVIRUS INFECTION$3,185
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: INTRAMUSCULAR INACTIVATED INFLUENZA A/H5N1 VACCINE IN HEALTHY AD$114
M01 · FY2008 · RR · contact PI
Health Impact of Congenial Cytomegalovirus Infection$614,832
R01 · FY2007 · AI · contact PI
INTRAMUSCULAR INACTIVATED INFLUENZA A/H5N1 VACCINE WITH DIFFERENT ADJUVANTS$379,175
M01 · FY2007 · RR · contact PI
CSL LIMITED INACTIVATED INFLUENZA VACCINE IN ADULTS > 18 TO < 65 YEARS OF AGE$261,561
M01 · FY2007 · RR · contact PI
INFLUENZA A/H5N1 VACCINE GIVEN ALONE OR WITH ALUMINUM HYDROXIDE TO YOUNG ADULTS$108,253
M01 · FY2007 · RR · contact PI
A PHASE I/II OF LC16M8, A MODIFIED VACCINIA VACCINE IN HEALTHY VOLUNTEERS$16,384
M01 · FY2007 · RR · contact PI
HEALTH IMPACT OF CONGENITAL CYTOMEGALOVIRUS INFECTION$8,777
M01 · FY2007 · RR · contact PI
INFLUENZA VACCINE IN CHILDREN 5-9 YEARS OF AGE$5,851
M01 · FY2007 · RR · contact PI
INFLUENZA IMMUNITY: PROTECTIVE MECHANISMS AGAINST A PRV$2,340
M01 · FY2007 · RR · contact PI
Health Impact of Congenial Cytomegalovirus Infection$615,092
R01 · FY2006 · AI · contact PI
IMMUNOGENICITY OF LC16M8, A MODIFIED VACCINIA VACCINE, IN HEALTHY VOLUNTEERS$133,878
M01 · FY2006 · RR · contact PI
INFLUENZA IMMUNITY: INFLUENZA VACCINE IN CHILDREN 5-9 YEARS OF AGE$104,969
M01 · FY2006 · RR · contact PI
INFLUENZA IMMUNITY: PROTECTIVE MECHANISMS AGAINST A PANDEMIC RESPIRATORY VIRUS$96,517
M01 · FY2006 · RR · contact PI
FLUZONE? IM INTRAMUSCULAR VACCINATION WITH FLUZONEIN HEALTHY ADULTS$70,720
M01 · FY2006 · RR · contact PI
INFLUENZA IMMUNITY: PROTECTIVE MECHANISMS AGAINST A PANDEMIC RESPIRATORY VIRUS$28,021
M01 · FY2006 · RR · contact PI
HEALTH IMPACT OF CONGENITAL C INFECTION$11,119
M01 · FY2006 · RR · contact PI
ACELLULAR PERTUSSIS COMBINED WITH DIPHTHERIA AND TETANUS VACCINES$1,334
M01 · FY2006 · RR · contact PI
Health Impact of Congenial Cytomegalovirus Infection$788,670
R01 · FY2005 · AI
INFLUENZA IMMUNITY: PROTECTIVE MECHANISMS AGAINST A PANDEMIC RESPIRATORY VIRUS$70,164
M01 · FY2005 · RR
INFLUENZA IMMUNITY: INFLUENZA VACCINE IN CHILDREN 5-9 YEARS OF AGE$32,409
M01 · FY2005 · RR
INFLUENZA IMMUNITY: UNIMMUNIZED CHILDREN BETWEEN 6 MONTHS AND 5 YEARS OF AGE$20,047
M01 · FY2005 · RR
HEALTH IMPACT OF CONGENITAL CYTOMEGALOVIRUS INFECTION$4,009
M01 · FY2005 · RR
ACELLULAR PERTUSSIS COMBINED WITH DIPHTHERIA AND TETANUS VACCINES$334
M01 · FY2005 · RR
Health Impact of Congenial Cytomegalovirus Infection$774,971
R01 · FY2004 · AI
A Multicenter, Double Blind, Randomized Dose-Response$201,498
M01 · FY2004 · RR
Influenza Immunity: Protective Mechanisms$65,783
M01 · FY2004 · RR
Immune Response to Influenza in Young Children Immunized with Trivalent$18,372
M01 · FY2004 · RR
Health Impact of Congenital Cytomegalovirus Infection$385,710
R01 · FY2003 · AI